2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1676 PPM1D-mutated myeloid neoplasms are clinically and genomically distinct from TP53-mutated disease despite convergence on the DNA damage response pathway

Talha Badar, MD, Mahesh Kumar, MD2, Terra Lasho, PhD3, Francyess Denis Oliva, MD4, Chenyu Lin, MD5, Mohamed El Mobachir el Kettani, MD6, Kashish Shah, MBBS7, Yael Kusne, MD, PhD8, Omer Jamy, MD9, Kendall Diebold, CNP, MSN10, Alexander Coltoff, MD11, Yao-Shan Fan, M.D., Ph.D.12, Liuyan Jiang, MD13, Rong He, MD14, Miles Thomas, MD15, Anand Ashwin Patel, MD16, David Viswanatha, MD17, Aref Al-Kali, M.D.18, Naseema Gangat, MBBS19, Mark R. Litzow, MD20, Hemant Murthy, MD21, Mohamed Kharfan-Dabaja, MD22, James Foran, FRCPC23, Mrinal M. Patnaik, MD, MBBS24
1 Mayo Clinic, Jacksonville, Florida, United States
2 Mayo Clinic, Jacksonville, Florida, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Duke University, Durham, North Carolina, United States
5 Duke University, Durham, North Carolina, United States
6 Mayo Clinic, Jacksonville, Florida, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 Mayo Clinic, Phoenix, Arizona, United States
9 University of Albama at Birmingham, Birmingham, Alabama, United States
10 University of Albama at Birmingham, Birmingham, Alabama, United States
11 Medical University of South Carolina, Charleston, South Carolina, United States
12 Mayo Clinic, Jacksonville, Florida, United States
13 Mayo Clinic, Jacksonville, Florida, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 University of Chicago, Chicago, Illinois, United States
16 University of Chicago, Chicago, Illinois, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Jacksonville, Florida, United States
22 Mayo Clinic, Jacksonville, Florida, United States
23 Mayo Clinic, Jacksonville, Florida, United States
24 Mayo Clinic, Rochester, Minnesota, United States

Background: PPM1D and TP53 are key DNA damage response (DDR) regulators frequently selected for under genotoxic stress. In our prior CH/CCUS study (Badar et al. Blood Adv 2026), PPM1D mutations (MT) were enriched in therapy-related CH/CCUS, occurred at low variant allele frequencies (VAF), and showed low rates of myeloid transformation even when TP53 co-mutated. The clinical impact of PPM1D MT in myeloid neoplasms (MN) remains unclear. We evaluated clinicogenomic features and outcomes of MN pts with PPM1D and TP53 mutations.

Methods: We conducted a multi-institutional study of 411 pts with MN from a larger cohort of 748 pts after excluding CH/CCUS and categorized them into three molecular gps: PPM1D-MT, PPM1D/TP53 co-MT, and TP53-MT. To adjust for MN heterogeneity, clinical responses, event-free survival (EFS), and overall survival (OS) were evaluated in the subgroup with bone marrow (BM) blasts >10% [MDS/AML]. Survival was estimated by Kaplan-Meier method and compared using Cox regression.

Results: Among 411 MN pts, 100 were PPM1D-MT, 61 PPM1D/TP53 co-MT, and 250 TP53-MT. Diagnoses: MDS (n=217), AML (n=108), MPN (n=77), CMML (n=9). Therapy-related MN were more frequent in PPM1D/TP53 vs PPM1D-only or TP53-only gps (52% vs 34% vs 32%; P=0.01). PPM1D-MT pts had higher median PPM1D VAF vs PPM1D/TP53 co-MT pts (12% vs 4%; P<0.001), while TP53 VAF was lower in PPM1D/TP53 vs TP53-MT (20% vs 39%; P<0.001). Complex karyotypes (CK) were less frequent in PPM1D-MT vs PPM1D/TP53 and TP53-MT gps (13% vs 61% vs 76%; P<0.001), and multi-hit TP53 was lower in PPM1D/TP53 vs TP53-MT (59% vs 78%; P=0.003). PPM1D-MT pts were more likely to have ASXL1, DNMT3A, and splicing factor co-mutations in comparison to PPM1D/TP53 and TP53-MT pts (22% vs 13% vs 8%, P=0.001; 22% vs 15% vs 11%, P=0.034; 22% vs 11 vs 12%, P=0.039).

Among 187 pts with MDS/CMML and BM blasts <10%, 44 were PPM1D-MT, 32 PPM1D/TP53 co-MT, and 111 TP53-MT (median age 70y); 9% had multiple PPM1D mutations, CK prevalence was 64%, while multi-hit TP53 was seen in 64%. Therapy-related MN was seen in 52%, with co-occurring ASXL1, DNMT3A, and splicing factor mutations in 8%, 15%, and 15%, respectively. PPM1D VAF was ≥ 20% in 20% of cases, and alloHCT was performed in 20% of pts. The mOS was not reached, 9.8, and 16.7 mo (P=0.008), favoring PPM1D-MT over PPM1D/TP53 (HR 0.28) and TP53-MT patients (HR 0.46); mEFS was 54.6, 6.9, and 9.3 mo (P<0.001), with PPM1D-MT patients having better outcomes (HR 0.22 and 0.19).

In the BM blast ≥10% subgroup (n=150), 30 were PPM1D-MT, 19 PPM1D/TP53 co-MT, and 101 TP53-MT; AML was the most frequent MN (80%, 53%, 63%; P=0.11). CK was present in 30%, 84%, and 92% (P<0.001), and multi-hit TP53 in 79% and 93% of PPM1D/TP53 and TP53-MT patients (P<0.001). Treatment differed across gps: intensive chemotherapy (IC) in 33%, 5%, 29%; hypomethylating agent (HMA)+venetoclax (VEN) in 30%, 47%, 46%. CR/CRh (complete remission ± partial hematologic recovery) rates were 43%, 21%, 32% (P=0.251); alloHCT (allogeneic transplant) rates were 20%, 11%, 20% (P=0.622). The mEFS was 4.3, 4.2, and 3.3 mo (P=0.09), with the PPM1D-MT group having a better EFS vs TP53-only (HR 0.60, P=0.038). mOS was 6.9, 4.5, and 8.0 mo (P=0.12); mOS censored at alloHCT was 5.3, 4.5, and 7.9 mo for PPM1D-MT, PPM1D/TP53, and TP53-MT gps (P=0.76).

On multivariable analysis among pts with BM blast ≥10%, after adjusting for multi-hit TP53 rather than CK, given co-linearity, PPM1D-MT only vs other gps was not independently associated with EFS (HR 0.70, P=0.313) or OS (HR 0.84, P=0.576). Multi-hit TP53 was independently adverse for EFS (HR 2.74, P=0.027) but not OS (HR 2.33, P=0.212). IC compared to HMA +/- VEN, was associated with inferior EFS (HR 2.17, P<0.001) but not for OS. The CR/CRh independently improved EFS (HR 0.43, P<0.001) but not OS (HR 0.62, P=0.110). AlloHCT independently improved both EFS (HR 0.39, P<0.001) and OS (HR 0.24, P=0.001).

Conclusions: PPM1D-MT MN represent a biologically distinct subset with clinicogenomic features that differ substantially from TP53-MT disease despite shared involvement of the DDR pathway. The favorable prognosis associated with isolated PPM1D mutations is restricted to lower-blast MDS/CMML and is lost in advanced MDS/AML, where multi-hit TP53, response to therapy, and alloHCT are the principal determinants of outcome.

 

 

Talha Badar, MD: Syndax - Honoraria; Takeda - Honoraria; Ascentage - Honoraria; Geron - Honoraria; Amgen - Honoraria; Takeda - Research Funding; Amgen - Research Funding